Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $50.37 USD
Change Today -1.12 / -2.18%
Volume 7.6M
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Albany Gate

Darkes Lane

Potters Bar, EN6 1AG

United Kingdom

Phone: 44 1707 853000

Fax: 44 1707 643148

Poland As part of the acquisition of Agila Specialties businesses (Agila), the company acquired an injectable manufacturing facility in Poland. In addition, the company operates a commercial business in Poland focused on the generic prescription market. Other European Locations The company has a notable presence in other European generic prescription markets, including Portugal. It also operates in various other European markets, including Ireland, the Nordic countries (principally Sweden and Finland), Belgium, the Czech Republic, and Hungary. Rest of World The company markets generic pharmaceuticals in Rest of World through subsidiaries in India, Australia, Japan, New Zealand, Brazil and Taiwan. Additionally, it has an export business, which is focused on countries in Africa and emerging markets throughout the world. The company also participates in a collaboration with Pfizer Japan Inc. (Pfizer Japan) to develop, manufacture, distribute and market generic drugs in Japan. Additionally, through Mylan India, it markets API to third parties and also supplies other subsidiaries. India Mylan India manufactures and supplies API for the company’s own products and pipeline, as well as for various third parties. Mylan India also produces a line of finished dosage form (FDF) products for the antiretroviral therapies (ARV) market, which are sold mostly outside of India. Additionally, Mylan India manufactures non-ARV FDF products that are marketed and sold to third parties by other operations around the world. The company has approximately 300 APIs in the market or under development. It produces API for use in the manufacture of its own pharmaceutical products, as well as for use by third parties, in a range of categories, including anti-bacterials, central nervous system agents, anti-histamine/anti-asthmatics, cardiovasculars, anti-virals, anti-diabetics, anti-fungals, proton pump inhibitors and pain management drugs. In 2013, the company added a portfolio of women’s health care products focused on hormone and infertility treatments along with nutritional supplements. Australia The company offers a portfolio of approximately 180 products in an aggregate of approximately 375 dosage strengths. Japan The company’s responsibilities in Japan primarily consist of managing operations, including research and development and manufacturing. In Japan, together with the company’s partner Pfizer Japan, it offers a portfolio of approximately 290 products in an aggregate of approximately 450 dosage strengths. New Zealand In New Zealand, the company offers a portfolio of approximately 90 products in an aggregate of approximately 150 dosage strengths. Brazil The company provides generic injectable products to the Brazilian hospital segment. Its sales into this market segment are made through distributors, as well as through tenders. Specialty This segment’s pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Mylan Specialty’s portfolio consists primarily of branded specialty injectable and nebulized products. A significant portion of Mylan Specialty’s revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that is sold in the U.S. and internationally. Mylan Specialty has worldwide rights to the epinephrine auto-injector, which is supplied to Mylan Specialty by a wholly owned subsidiary of Pfizer Inc. Anaphylaxis is a severe allergic reaction that is rapid in onset and may cause death, either through swelling that shuts off airways or through significant drop in blood pressure. Perforomist Inhalation Solution, Mylan Specialty’s Formoterol Fumarate Inhalation Solution, was launched in 2007. Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for long-term, twice-daily administration in the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients, including those with chronic bronchitis and emphysema. Mylan Specialty has various the U.S. and international patents p


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $50.37 USD -1.12

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,804 JPY +23.00
Becton Dickinson and Co $142.83 USD -0.12
Henry Schein Inc $139.40 USD +0.72
Perrigo Co PLC $185.42 USD -2.77
WW Grainger Inc $223.23 USD -0.51
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 24.9x
Price/Sales 3.0x
Price/Book 2.6x
Price/Cash Flow 27.7x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at